Time to reconsider the use of beta-blockers after myocardial infarction

The use of beta-blockers after an episode of myocardial infarction is well-established in clinical practice in the last few decades.
However, most trials that have shown a benefit of beta-blocker treatment after myocardial infarction included patients with large myocardial infarctions and were conducted in an era before modern biomarker-based diagnosis of myocardial infarction and treatment with percutaneous coronary intervention. Also, antithrombotic agents and high-potency statins have managed to significantly improve the prognosis of coronary artery disease patients.
In a recent trial, which included more than 5000 patients, it is demonstrated that if systolic function is maintained after an episode of myocardial infarction the use of beta blockers may be reconsidered.
Specifically, in those with acute myocardial infarction who underwent early coronary angiography and had a preserved left ventricular ejection fraction (≥50%), long-term beta-blocker treatment did not show any comparative therapeutic benefit opposed to the group of patients who did not received beta- blockers.
Reference:
The New England Journal of Medicine
Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction
N. Engl. J. Med 2024 Apr 07
